Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: A randomized controlled trial

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Forni, Valentina ^a,b   Bianchi, Giorgia ^a   Ogna, Adam ^a   Salvadé, Igor ^a   Vuistiner, Philippe ^c   Burnier, Michel ^b   Gabutti, Luca ^a  

^a Ospedale Regionale Locarno   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Erythropoietin stimulating agents; Hemoglobin; Reticulocytes; Variability

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; ERYTHROPOIETIN; MACROGOL DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; AGED; ANALOGS AND DERIVATIVES; DRUG ADMINISTRATION; DRUG EFFECTS; EPIDEMIOLOGY; METABOLISM; MIDDLE AGED; PROCEDURES; RENAL REPLACEMENT THERAPY; RETICULOCYTE; SUBCUTANEOUS DRUG ADMINISTRATION; SWITZERLAND; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; RETICULOCYTE COUNT; RETICULOCYTES; SWITZERLAND; TREATMENT OUTCOME;

EID: 84880335862     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-157     Document Type: Article

References (23)

1. Hemoglobin variability in epoetin-treated hemodialysis patients. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB, Kidney Int 2003 64 1514 1521 10.1046/j.1523-1755.2003.00229.x 12969173 (Pubitemid 37153820)
2. Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Singh AK, Milford E, Fishbane S, Keithi-Reddy SR, Kidney Int 2008 74 679 683 10.1038/ki.2008.59 18337717
3. Evidence and implications of haemoglobin cycling in anaemia management. Fishbane S, Berns JS, Nephrol Dial Transplant 2007 22 2129 2132 10.1093/ndt/gfm384 17595177 (Pubitemid 47244687)
4. Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: is it feasible? Gabutti L, Nobile F, Forni V, Rigamonti F, Weibel N, Burnier M, BMC Nephrol 2011 12 11 10.1186/1471-2369-12-11 21332992
5. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Fishbane S, Berns JS, Kidney Int 2005 68 1337 1343 10.1111/j.1523-1755.2005.00532.x 16105069 (Pubitemid 43246455)
6. Optimizing the use of erythropoietic agents- pharmacokinetic and pharmacodynamic considerations. Macdougall IC, Nephrol Dial Transplant 2002 17 Suppl 5 66 70 12091611 (Pubitemid 34823076)
7. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Joy MS, Ann Pharmacother 2002 36 1183 1192 12086553 (Pubitemid 34755797)
8. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B, Clin J Am Soc Nephrol 2006 1 1211 1215 10.2215/CJN.00730306 17699350
9. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, Clin J Am Soc Nephrol 2007 2 637 646 10.2215/CJN.03631006 17699476
10. Mircera; Annex I; Summary of Product Characteristics. Roche Pharma, European Medicines Agency 2008
11. Documed, Mircera Compendium Suisse des Médicaments 2009
12. Analysis of affective instability in ecological momentary assessment: Indices using successive difference and group comparison via multilevel modeling. Jahng S, Wood PK, Trull TJ, Psychol Methods 2008 13 354 375 19071999
13. Pinheiro J, Bates D, DebRoy S, Deepayan S, Linear and Nonlinear Mixed Effects Models Package "nlme" Version 3.1-110 2013.
14. Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Bellizzi V, Minutolo R, Terracciano V, Iodice C, Giannattasio P, De NL, Conte G, Di Iorio BR, Am J Kidney Dis 2002 40 549 555 10.1053/ajkd.2002.34913 12200807 (Pubitemid 34971284)
15. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Gunnell J, Yeun JY, Depner TA, Kaysen GA, Am J Kidney Dis 1999 33 63 72 10.1016/S0272-6386(99)70259-3 9915269 (Pubitemid 29031210)
16. Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. de Francisco AL, Stenvinkel P, Vaulont S, NDT Plus 2009 2 18 i26 10.1093/ndtplus/sfn176 19461856
17. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD, Am J Kidney Dis 2003 42 761 773 10.1016/S0272-6386(03)00915-6 14520627 (Pubitemid 37187377)
18. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Ebben JP, Gilbertson DT, Foley RN, Collins AJ, Clin J Am Soc Nephrol 2006 1 1205 1210 10.2215/CJN.01110306 17699349
19. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. Ifudu O, Feldman J, Friedman EA, N Engl J Med 1996 334 420 425 10.1056/NEJM199602153340702 8552143 (Pubitemid 26055841)
20. Fluctuations in haemoglobin levels in haemodialysis patients receiving intravenous epoetin alfa or intravenous darbepoetin alfa. Walker R, Pussell BA, Nephrology (Carlton) 2007 12 448 451 10.1111/j.1440-1797.2007.00802.x (Pubitemid 47366636)
21. Fluctuations in haemoglobin levels in haemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha. Walker R, Pussell BA, Nephrology (Carlton) 2009 14 689 695 10.1111/j.1440-1797. 2009.01166.x
22. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K, J Am Soc Nephrol 2006 17 1181 1191 10.1681/ASN.2005090997 16565261
23. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D, Lancet 2007 370 1415 1421 10.1016/S0140-6736(07)61599-2 17950856 (Pubitemid 47576167)